LXW7 TFA,99.17%

产品编号:Bellancom-P0178A| 分子式:C31H49F3N12O14S2| 分子量:934.92

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用,

货号 包装 价格 库存与货期 购买量 操作
Bellancom-P0178A
13500.00 杭州 北京(现货)
Bellancom-P0178A
28000.00 杭州 北京(现货)
Bellancom-P0178A
38000.00 杭州 北京(现货)

增值税发票√顺丰快递√订货电话:18601927057

LXW7 TFA

产品介绍 LXW7 TFA 是一种含 Arg-Gly-Asp (RGD) 的环状肽,是一种整合素 αvβ3 抑制剂,对 αvβ3 整联蛋白具有很高的结合亲和力,IC50 为 0.68 μM。LXW7 TFA 可增强 VEGFR-2 磷酸化和 ERK1/2 活化。具有抗炎活性。
生物活性

LXW7 TFA, a cyclic peptide containing Arg-Gly-Asp (RGD), is an integrin αvβ3 inhibitor. LXW7 has a high binding affinity to αvβ3 integrin with an IC50 of 0.68 μM. LXW7 TFA increases phosphorylation of VEGFR-2 and activation of ERK1/2. Anti-inflammatory effect.

体外研究

LXW7 specially binds to αvβ3 integrin (Kd=76±10 nM). LXW7 binds strongly to αvβ3-K562 cells, weakly to αvβ5-K562 cells and αIIbβ3-K562 cells, and no binding to K562 cells. LXW7 has great potential as a highly efficient peptide ligand for targeted imaging and drug delivery.
LXW7 acts as a potent and specific endothelial progenitor cells (EPCs) and endothelial cells (ECs) targeting ligand.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

LXW7 (100 μg/kg; intravenous injection) significantly lowers infarct volumes and brain water content (BWC) LXW7-treated rats. The LXW7 treatment lowers the expression of pro-inflammatory cytokines.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male Sprague-Dawley rats (250-280 g) subjected to middle cerebral artery occlusion (MCAO)
Dosage: 100 μg/kg
Administration: Intravenous injection
Result: Infarct volumes and BWC were significantly lower compared to those in the MCAO+PBS (control) group.
体内研究

LXW7 (100 μg/kg; intravenous injection) significantly lowers infarct volumes and brain water content (BWC) LXW7-treated rats. The LXW7 treatment lowers the expression of pro-inflammatory cytokines.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male Sprague-Dawley rats (250-280 g) subjected to middle cerebral artery occlusion (MCAO)
Dosage: 100 μg/kg
Administration: Intravenous injection
Result: Infarct volumes and BWC were significantly lower compared to those in the MCAO+PBS (control) group.
性状Solid
溶解性数据
运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Sealed storage, away from moisture

Powder -80°C 2 years
-20°C 1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

参考文献

相关文档

化学品安全说明书(MSDS)

下载MSDS

质检证书(COA)

相关产品


服务热线

13911702513
18601927057

微信客服